Literature DB >> 26494371

Changes in glycosylation of human blood plasma chitotriosidase in patients with type 2 diabetes.

Ewa Żurawska-Płaksej, Ewa Maria Kratz, Mirosława Ferens-Sieczkowska, Maria Knapik-Kordecka, Agnieszka Piwowar.   

Abstract

Human blood plasma chitotriosidase (CHIT1) is a glycoprotein with chitinolytic activity with not fully elucidated biological function. Its increased level is observed in type 2 diabetes mellitus (T2DM) and is associated with development of diabetic complications. The CHIT1 glycosylation profile and degree is still poorly studied and never investigated in T2DM. Therefore the aim of the present study was to examine the association between glycosylation profile and degree and diabetes with accompanying nephropathy. In blood plasma of 28 patients with T2DM and 11 healthy subjects the CHIT1 concentration and specific activity were examined. The profile and degree of CHIT1 glycosylation were determined by lectin-ELISA using lectins specific to O-glycans (Jacalin, MPL, VVL) and sialo-specific SNA and MAA. We revealed that both concentration and specific activity of CHIT1 significantly increased in T2DM, especially in nephropathy with elevated albuminuria. The relative reactivities with lectins, except Jacalin, decreased progressively with T2DM occurrence and albuminuria progression. The most significant differences were observed between control vs. albuminuric group (Micro and Macro). It is also possible that the observed differences in immunoblotting pattern in molecular masses of CHIT1 bands between T2DM patients and healthy subjects may be caused by the differences in degree of CHIT1 glycosylation. The analysis of CHIT1 glycosylation status and the determination of CHIT1 concentration together with its enzymatic activity in blood plasma might constitute additional valuable diagnosis tools for the evaluation the T2DM patients with accompanying nephropathy. Extension of the lectin panel specific to O-glycans occurs useful for the further research using microarray formats, which are expected to accelerate “lectin-based glycan profiling” of glycoproteins.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26494371     DOI: 10.1007/s10719-015-9629-z

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  47 in total

Review 1.  Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds.

Authors:  Robert G Spiro
Journal:  Glycobiology       Date:  2002-04       Impact factor: 4.313

Review 2.  Insect chitinase and chitinase-like proteins.

Authors:  Yasuyuki Arakane; Subbaratnam Muthukrishnan
Journal:  Cell Mol Life Sci       Date:  2009-10-09       Impact factor: 9.261

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Haptoglobin glycoforms in a case of carbohydrate-deficient glycoprotein syndrome.

Authors:  M Ferens-Sieczkowska; A Midro; B Mierzejewska-Iwanowska; K Zwierz; I Katnik-Prastowska
Journal:  Glycoconj J       Date:  1999-10       Impact factor: 2.916

5.  Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase.

Authors:  G H Renkema; R G Boot; A Strijland; W E Donker-Koopman; M van den Berg; A O Muijsers; J M Aerts
Journal:  Eur J Biochem       Date:  1997-03-01

6.  [Serum activity of chitotriosidase, lysozyme and cathepsin H in patients with lung cancer and patients with inflammatory exudate (preliminary report)].

Authors:  Krzysztof Gołab; Ewa Passowicz-Muszyńska; Renata Jankowska; Maria Warwas
Journal:  Pol Merkur Lekarski       Date:  2009-03

Review 7.  Obesity, inflammation and endothelial dysfunction.

Authors:  M Iantorno; U Campia; N Di Daniele; S Nistico; G B Forleo; C Cardillo; M Tesauro
Journal:  J Biol Regul Homeost Agents       Date:  2014 Apr-Jun       Impact factor: 1.711

Review 8.  The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance.

Authors:  Jindrich Chmelar; Kyoung-Jin Chung; Triantafyllos Chavakis
Journal:  Thromb Haemost       Date:  2013-01-31       Impact factor: 5.249

Review 9.  Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling.

Authors:  Mansi Prakash; Manish Bodas; Divya Prakash; Neelu Nawani; Madhukar Khetmalas; Abul Mandal; Cecilia Eriksson
Journal:  Cell Signal       Date:  2013-04-02       Impact factor: 4.315

10.  Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease.

Authors:  Christoffer Rosén; Carl-Henrik Andersson; Ulf Andreasson; José L Molinuevo; Maria Bjerke; Lorena Rami; Albert Lladó; Kaj Blennow; Henrik Zetterberg
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2014-07-31
View more
  4 in total

Review 1.  Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases.

Authors:  Peter Goettig
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

2.  Protein N-glycosylation aberrations and glycoproteomic network alterations in osteoarthritis and osteoarthritis with type 2 diabetes.

Authors:  Yi Luo; Ziguang Wu; Song Chen; Huanhuan Luo; Xiaoying Mo; Yao Wang; Jianbang Tang
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

3.  O-Glycosylation Changes in Serum Immunoglobulin G Are Associated with Inflammation Development in Advanced Endometriosis.

Authors:  Katarzyna Sołkiewicz; Monika Kacperczyk; Hubert Krotkiewski; Marcin Jędryka; Ewa Maria Kratz
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

4.  Trehalose Activates Hepatic and Myocardial Autophagy and Has Anti-Inflammatory Effects in db/db Diabetic Mice.

Authors:  Tatiana A Korolenko; Marina V Ovsyukova; Nataliya P Bgatova; Igor D Ivanov; Svetlana I Makarova; Valentin A Vavilin; Alexey V Popov; Ekaterina I Yuzhik; Elena V Koldysheva; Erik C Korolenko; Evgeny L Zavjalov; Tamara G Amstislavskaya
Journal:  Life (Basel)       Date:  2022-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.